store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LFHP-1c, a neuroprotective PGAM5 inhibitor, demonstrates efficacy in preserving blood-brain barrier integrity following ischemic stroke. It achieves this by binding to endothelial PGAM5, thereby inhibiting its phosphatase activity and its interaction with NRF2. LFHP-1c has shown protective effects both in vitro and in vivo [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | LFHP-1c, a neuroprotective PGAM5 inhibitor, demonstrates efficacy in preserving blood-brain barrier integrity following ischemic stroke. It achieves this by binding to endothelial PGAM5, thereby inhibiting its phosphatase activity and its interaction with NRF2. LFHP-1c has shown protective effects both in vitro and in vivo [1]. |
In vitro | LFHP-1c pre-treatment at concentrations of 1, 2, or 5 μmol/L for 9 hours, followed by hypoxia, enhanced NRF2 protein expression and facilitated its nuclear translocation in rat brain microvascular endothelial cells (rBMECs) [1]. |
In vivo | LFHP-1c administered intravenously at a dosage of 5 mg/kg (静脉注射; 2 剂) was effective in preventing blood-brain barrier (BBB) disruption following transient middle cerebral artery occlusion (tMCAO) in rats [1]. At a lower dose and increased volume of 3 mg/kg, 1 mL/kg (静脉注射; 8 剂), LFHP-1c ameliorated cerebral ischemic damage in a tMCAO model via the PGAM5-NRF2 axis [1]. |
Molecular Weight | 873.13 |
Formula | C55H64N6O4 |
CAS No. | 2102347-47-5 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LFHP-1c 2102347-47-5 Metabolism Phospholipase inhibitor inhibit